U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ACHIRAL
Molecular Formula C27H25N9O6S.2Na
Molecular Weight 649.589
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TEZOSENTAN DISODIUM

SMILES

[Na+].[Na+].COC1=CC=CC=C1OC2=C(OCCO)N=C(N=C2[N-]S(=O)(=O)C3=CC=C(C=N3)C(C)C)C4=CC(=NC=C4)C5=NN=N[N-]5

InChI

InChIKey=LJEMFZYMXONDDJ-UHFFFAOYSA-N
InChI=1S/C27H25N9O6S.2Na/c1-16(2)18-8-9-22(29-15-18)43(38,39)34-26-23(42-21-7-5-4-6-20(21)40-3)27(41-13-12-37)31-24(30-26)17-10-11-28-19(14-17)25-32-35-36-33-25;;/h4-11,14-16,37H,12-13H2,1-3H3;;/q-2;2*+1

HIDE SMILES / InChI

Molecular Formula Na
Molecular Weight 22.98976928
Charge 1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C27H26N9O6S
Molecular Weight 604.617
Charge -1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: The description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/15055997 | https://clinicaltrials.gov/ct2/show/NCT00524433 | https://www.ncbi.nlm.nih.gov/pubmed/14632537 | https://clinicaltrials.gov/ct2/show/NCT01077297 | https://www.ncbi.nlm.nih.gov/pubmed/22474738

Tezosentan (Veletri; Ro 61–0612) is a dual endothelin receptor antagonist that has been shown to improve cardiac output, decrease pulmonary capillary wedge pressure, and reduce pulmonary and systemic vascular resistance in initial clinical studies in acutely decompensated heart failure. Tezosentan is a water-soluble ET-1 receptor antagonist with high affinity to both ETA and ETB receptors but greater potency for the ETA receptor subtype. Clinical studies demonstrated mixed results for Tezosentan regarding its efficacy and tolerability in the management of decompensated heart failure. The side effects of Tezosentan include a headache, nausea, and hypotension.

Originator

Curator's Comment: # F. Hoffmann-La Roche Ag

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
23.0 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
50th Annual scientific sessions of the American college of cardiology.
2001 Apr 10
Effects of tezosentan, a dual endothelin receptor antagonist, on the cardiovascular and renal systems of neonatal piglets.
2001 Dec
Role of endogenous endothelin on coronary reflow after cardioplegic arrest.
2001 Dec
Endothelin receptor blockade improves oxygenation in contralateral TRAM flap tissue in pigs.
2001 Jul
Clinical Trials Update: CAPRICORN, COPERNICUS, MIRACLE, STAF, RITZ-2, RECOVER and RENAISSANCE and cachexia and cholesterol in heart failure. Highlights of the Scientific Sessions of the American College of Cardiology, 2001.
2001 Jun
Tezosentan inhibits both equinatoxin II and endotelin-1 induced contractions of isolated porcine coronary artery in a similar way.
2002 Aug
Endogenous endothelin increases gallbladder tone and leads to acute cholecystitis in the Australian possum.
2004 Feb
Role of endothelin-1 and thromboxane A2 in the pulmonary hypertension induced by heparin-protamine interaction in anesthetized dogs.
2004 Jan
Differentiated and dose-related cardiovascular effects of a dual endothelin receptor antagonist in endotoxin shock.
2004 May
Renal blood flow in sepsis.
2005 Aug
Endothelin-1 causes systemic vasodilatation in anaesthetised turtles (Trachemys scripta) through activation of ETB-receptors.
2005 Oct
The role of indomethacin and tezosentan on renal effects induced by Bothrops moojeni Lys49 myotoxin I.
2006 Jun 15
NO and prostanoids blunt endothelin-mediated coronary vasoconstrictor influence in exercising swine.
2006 Nov
Patents

Patents

Sample Use Guides

single infusion of tezosentan 5mg/h over 30 min corresponding to 2.5 mg
Route of Administration: Intravenous
Aortic valves were obtained from 16 patients at the time of aortic valve replacement surgery. After surgical removal, each valve was divided approximately into 15 pieces. Valve pieces (4 mm diameter) of normal and sclerotic aortic valves were cultured in αMEM (Gibco, Paisley, UK), supplemented with 10% heat-inactivated fetal bovine serum (FBS; Autogen Bioclear, Wiltshire, UK), 20 mM HEPES (Gibco) 100 U/ml penicillin, 0.1 mg/ml streptomycin (Gibco) and 2 mM L-glutamine (Gibco) at 37°C in 5% CO2 and 95% air. For the measurement of radioactivity in cell culture experiments, valve pieces from two normal patients (resulting in 30 valve pieces) as well as six stenotic patients (resulting in 90 valve pieces) were inserted into the 24-well plates, the medium was changed, and the test drugs (125I-ET-1, 10 nmol/l; ET-1, 100 µmol/l; tezosentan, 10 nmol/l) were added on the second day of culture. After 20 min and 3 h of incubation, the valves were washed three times with DPBS (BioWhittaker, Lonza, Belgium). Radioactivity was measured using a Wallac Multigamma counter (Wallac, Turku, Finland) and results were expressed as counts per minute.
Substance Class Chemical
Created
by admin
on Mon Mar 31 21:24:37 GMT 2025
Edited
by admin
on Mon Mar 31 21:24:37 GMT 2025
Record UNII
2Q53CXJ1D6
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
TEZOSENTAN DISODIUM
Common Name English
TEZOSENTAN SODIUM SALT
MI  
Preferred Name English
DISODIUM (6-(2-HYDROXYETHOXY)-5-(2-METHOXYPHENOXY)-2-(2-(2,3,4-TRIAZA-5-AZANIDA-1-YL)-4-PYRIDYL)PYRIMIDIN-4-YL)-((5-ISOPROPYL-2-PYRIDYL)SULFONYL)AZANIDE
Common Name English
N-(6-(2-HYDROXYETHOXY)-5-(2-METHOXYPHENOXY)-2-(2-(1H-TETRAZOL-5-YL)PYRIDIN-4-YL)PYRIMIDIN-4-YL)-5-ISOPROPYLPYRIDINE-2-SULFONAMIDE DISODIUM SALT
Common Name English
TEZOSENTAN SODIUM SALT [MI]
Common Name English
2-PYRIDINESULFONAMIDE, N-(6-(2-HYDROXYETHOXY)-5-(2-METHOXYPHENOXY)-2-(2-(2H-TETRAZOL-5-YL)-4-PYRIDINYL)-4-PYRIMIDINYL)-5-(1-METHYLETHYL)-, SODIUM SALT (1:2)
Systematic Name English
VELETRI
Brand Name English
RO-61-0612
Code English
Code System Code Type Description
MERCK INDEX
m10670
Created by admin on Mon Mar 31 21:24:37 GMT 2025 , Edited by admin on Mon Mar 31 21:24:37 GMT 2025
PRIMARY Merck Index
FDA UNII
2Q53CXJ1D6
Created by admin on Mon Mar 31 21:24:37 GMT 2025 , Edited by admin on Mon Mar 31 21:24:37 GMT 2025
PRIMARY
PUBCHEM
6918475
Created by admin on Mon Mar 31 21:24:37 GMT 2025 , Edited by admin on Mon Mar 31 21:24:37 GMT 2025
PRIMARY
CAS
180384-58-1
Created by admin on Mon Mar 31 21:24:37 GMT 2025 , Edited by admin on Mon Mar 31 21:24:37 GMT 2025
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY